Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11162148 | 0.95 | LMNA (0.49) | ARCFTRLMNACYP19A1CYP1A2 | |
| SCHEMBL11160756 | 0.86 | ALDH1A1 (0.51) | LMNACYP1A2CYP2C9RAB9AALDH1A1 | |
| SCHEMBL8126133 | 0.83 | AR (0.51) | ARCFTRLMNANPC1CYP1A2 | |
| SCHEMBL11132734 | 0.82 | AR (0.43) | ARCFTRLMNANPC1CYP1A2 | |
| SCHEMBL5327493 | 0.82 | AR (0.52) | ARCFTRLMNANPC1CYP1A2 | |
| SCHEMBL5330156 | 0.81 | AR (0.57) | ARCFTRNPC1CYP1A2CYP2C9 | |
| SCHEMBL11097622 | 0.80 | ALDH1A1 (0.56) | LMNARAB9AMAPTALDH1A1KDM4E | |
| SCHEMBL11093772 | 0.80 | ALDH1A1 (0.59) | LMNANPC1CYP1A2CYP2C9RAB9A | |
| SCHEMBL11163273 | 0.80 | ALDH1A1 (0.59) | LMNANPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL11099111 | 0.79 | AR (0.52) | ARCFTRMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7182934-B2 | Ultrasonic contrast agents; aqueous suspension | GE HEALTHCARE AS (NO) | 2007-02-27 | — | — | US | disclosed |
| EP-0971747-B1 | CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2005-12-28 | — | — | EP | disclosed |
| US-20050201930-A1 | Contrast agents | GE HEALTHCARE AS (NO) | 2005-09-15 | — | — | US | disclosed |
| US-6921525-B2 | Contrast agents | AMERSHAM HEALTH AS (NO) | 2005-07-26 | — | — | US | disclosed |
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AMERSHAM HEALTH AS (NO) | 2003-12-11 | — | — | US | disclosed |
| US-6524552-B2 | Imaging cardiovascular disorders | GE HEALTHCARE AS (NO) | 2003-02-25 | — | — | US | disclosed |
| US-20010016587-A1 | Contrast agents | NYCOMED IMAGING AS | 2001-08-23 | — | — | US | disclosed |
| US-6264914-B1 | CONTAINING IMIDAZOLE RING | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| EP-0971747-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998018496-A2 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-05-07 | — | — | WO | disclosed |
| EP-0028834-B1 | IMIDAZOLE-5-ACETIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-01-18 | — | — | EP | disclosed |
| US-4355040-A | Hypotensive imidazole-5-acetic acid derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| EP-0028834-A1 | Imidazole-5-acetic acid derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030228254-A1 | Diagnosis of cardiovascular disorders | AGTR1, AGTR2, AGT | AR 329/4885CFTR 3683/4885LMNA 193/4885 |
| US-20010016587-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | AR 334/4885CFTR 1997/4885LMNA 216/4885 |
| US-20050201930-A1 | Contrast agents | AGTR1, AGTR2, VIPR1 | AR 287/4885CFTR 2555/4885LMNA 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.